Preview

PDF Restricted - Request a copy 196Kb

There is considerable interest and debate concerning the place of generic substitution, especially relating to antiepileptic drugs (AEDs). Sadly, one of the causes of the ongoing debate is confusion, often intentionally fueled by the pharmaceutical industry among health professionals and patients regarding the regulatory determination of bioequivalence. Few understand the correct definition. It is often erroneously stated that to be considered bioequivalent there is an allowed difference in the extent and rate of absorption of 80% to 125% between a generic drug product and the branded standard. This is false and implies there is a wide leniency allowed, with varying clinical outcomes probable. This myth needs to be countered to reassure the safety of patients. A balanced review of the issues surrounding the generic substitution of AEDs is presented.

Item Type:	Refereed Article
Research Division:	Medical and Health Sciences
Research Group:	Pharmacology and Pharmaceutical Sciences
Research Field:	Clinical Pharmacology and Therapeutics
Objective Division:	Health
Objective Group:	Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:	Nervous System and Disorders
UTAS Author:	Peterson, GM (Professor Gregory Peterson)
ID Code:	71695
Year Published:	2011
Web of Science® Times Cited:	2
Deposited By:	Pharmacy
Deposited On:	2011-08-02
Last Modified:	2017-08-14
Downloads:	1 View Download Statistics